ACADIA Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /66
ACADIA Pharmaceuticalsの総株主資本は$577.2M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$976.9Mと$399.7Mです。 ACADIA Pharmaceuticalsの EBIT は$112.2Mで、利息カバレッジ比率-4.8です。現金および短期投資は$565.3Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | -4.8x |
| 現金 | US$565.33m |
| エクイティ | US$577.18m |
| 負債合計 | US$399.69m |
| 総資産 | US$976.87m |
財務の健全性に関する最新情報
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18財務状況分析
短期負債: ACADの 短期資産 ( $788.3M ) が 短期負債 ( $343.9M ) を超えています。
長期負債: ACADの短期資産 ( $788.3M ) が 長期負債 ( $55.7M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ACADは負債がありません。
負債の削減: ACAD過去 5 年間負債を抱えていません。
債務返済能力: ACADには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: ACADには負債がないため、利息支払い の負担は問題になりません。